CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
May 15 2020 - 8:30AM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced that four abstracts have been accepted
for poster presentation at the American Association for Cancer
Research (AACR) Virtual Annual Meeting II, which will take place
from June 22 to 24, 2020.
Session information is available online via the Annual Meeting
Itinerary Planner through the AACR website at www.aacr.org.
Title: Functional and single-cell assessment of
CRISPR-modified CAR-T cells from NSCLC patients and healthy donors
Session Title: Adoptive Cell Therapy
1E-Poster Number: 879Abstract
Number: 3338
Title: Allogeneic CAR-T cell products
containing 10 gene edits using CRISPR/Cas9 can retain full
functionality in vivo and in vitro Session
Title: Adoptive Cell Therapy 1E-Poster
Number: 880Abstract Number: 4647
Title: Allogeneic anti-PTK7 CAR-T cells for the
treatment of solid tumors Session Title:
Adoptive Cell Therapy 3E-Poster Number:
3243Abstract Number: 6231
Title: Targeting T cell lymphomas with
CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T
cells Session Title: Adoptive Cell Therapy
5E-Poster Number: 6595Abstract
Number: 3308
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
partnerships with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in San Francisco,
California and London, United Kingdom. For more information, please
visit www.crisprtx.com.
CRISPR Investor Contact:Susan Kim+1
617-307-7503susan.kim@crisprtx.com
CRISPR Media Contact:Rachel EidesWCG on behalf
of CRISPR+1 617-337-4167 reides@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024
